Journal

Bladder cancer biomarker screening based on non-targeted urine metabolomics

Read time: 1 mins

Published:1st Jan 2022

Author: Li J, Cheng B, Xie H, Zhan C, Li S, Bai P.

Source: International Urology and Nephrology

Availability: Pay for access, or by subscription

Ref.:Int Urol Nephrol. 2022 Jan;54(1):23-29.

DOI:10.1007/s11255-021-03080-6

Bladder cancer biomarker screening based on non-targeted urine metabolomics

Purpose: Bladder cancer is one of the most common malignancies of the urinary system, and its screening relies heavily on invasive cystoscopy, which increases the risk of urethral injury and infection. This study aims to use non-targeted metabolomics methods to screen for metabolites that are significantly different between the urine of bladder cancer patients and cancer-free controls.

Methods: In this study, liquid chromatography-mass spectrometry was used to analyze the urine of bladder cancer patients (n = 57) and the cancer-free controls (n = 38) by non-targeted metabolomic analysis and metabolite identification.

Results: The results showed that there were significant differences in the expression of 27 metabolites between bladder cancer patients and the cancer-free controls.

Conclusion: In the multivariate statistical analysis of this study, the urinary metabolic profile data of bladder cancer patients were analyzed, and the receiver operating characteristic curve analysis showed that it is possible to perform non-invasive clinical diagnoses of bladder cancer through these candidate biomarkers.

Read abstract on library site Access full article